Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us
You are here :

C3001a

  • Zoom
    C3001a
  • C3001a
Cat No: 31064
Biochemicals - Ion Channel Modulation
Cayman

C3001a is an activator of the two-pore domain potassium channels K2P2.1/TREK1 and K2P10.1/TREK2.{59302} It increases current amplitude in HEK293T cells expressing K2P2.1/TREK1 or K2P10.1/TREK2 (EC50s = 12.81 and 11.31 µM, respectively, for the human c...

More

This product can only be bought through Cayman Chemical. Please contact us.

Territorial Availability: Available through Bertin Technologies only in France
Synonyms:
  • (1S,3R)-3-[[[4-(6-methyl-2-benzothiazolyl)phenyl]amino]carbonyl]-cyclopentanecarboxylic acid
Correlated keywords:
  • C3001 a twopore K2P 2.1 10.1 TREK 1 2 HEK 293T
Product Overview:
C3001a is an activator of the two-pore domain potassium channels K2P2.1/TREK1 and K2P10.1/TREK2.{59302} It increases current amplitude in HEK293T cells expressing K2P2.1/TREK1 or K2P10.1/TREK2 (EC50s = 12.81 and 11.31 µM, respectively, for the human channels). C3001a is selective for K2P2.1/TREK1 and K2P10.1/TREK2 over a panel of five additional K2P channels at 10 µM. In vivo, C3001a (10 mg/kg) reduces edema and pancreatic necrosis in a mouse model of acute pancreatitis. It reduces mechanical and thermal hyperalgesia in a mouse model of chronic inflammatory pain induced by complete Freund's adjuvant (CFA). C3001a (5 mg/kg) also reduces cold hyperalgesia in a mouse model of neuropathic pain induced by spared nerve injury (SNI).
Size 1 mg
Shipping dry ice
CAS Number 2415154-29-7
Molecular Formula C21H20N2O3S
SMILES CC1=CC=C2N=C(SC2=C1)C3=CC=C(C=C3)NC([C@H]4C[C@@H](C(O)=O)CC4)=O
Molecular Weight 380,5
Formulation A crystalline solid
Purity ≥98%
Custom Code 2934.20
UNSPSC code 12352100

Click here to ask for your quote and get 15% off Cayman's products.

 

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

Search